Antibiotic raw materials market is different

Since the late 1950s, China’s North China Pharmaceuticals has built the largest streptomycin fermentation plant in Asia. Since then, China has been the world’s largest producer and exporter of streptomycin. There are dozens of pharmaceutical companies that have obtained approval for the production of streptomycin throughout the country, but the output of North China Pharmaceutical is still the largest.

In response to the current status of the domestic antibiotics market, the Champ Consulting pharmaceutical industry analysts believe that the relevant four major categories of APIs will present the following trends:

First, in the past few decades, because there has been no profit in the production of streptomycin in developed regions, Western countries have changed the import of streptomycin from China to maintain clinical treatment needs. Since India is a major country of tuberculosis, India is also one of the major export destinations for streptomycin in China.

Second, gentamicin antibiotic products were first developed by western countries, but China has become the largest gentamicin producer and exporter in the world; the output of the country's three largest gentamicin fermentation plants accounts for approximately More than 60% of the total gentamicin production. It is reported that the total amount of gentamicin raw materials exported to China last year was about 40 million US dollars, a slight decrease from the previous year.

Third, due to the good export momentum of China's amikacin raw materials in the past few years, some domestic pharmaceutical companies have increased the production of amikacin, resulting in a sharp increase in the production of amikacin. However, due to the reduction in the demand for this drug abroad, it has resulted in poor export and partial product backlog.

The fourth is that netilmics antibiotics are very popular in the international market because of their remarkable clinical medical effects. However, due to reasons such as low yield of fermentation, the product has been a “short board product” of aminoglycoside antibiotics in China for a long period of time, and its output is tens of tons per year. With the continuous development of technology, production of netilmicin in our country began to rise.

The “2012-2016 Antibiotic Market In-Depth Survey and Investment Strategy Consultation Report” published by Shangpu Consulting showed that the market prospect of aminoglycoside antibiotics is good. Due to the new pharmacological effects of glycoside antibiotics and the successive development of new aminoglycoside antibiotic derivatives, in the next few years, antibiotics such as aminoglycosides are expected to rejuvenate and become an international pharmaceutical market. Bestsellers.